1RVMD Fundamental Analysis - REVOLUTION MEDICINES INC

Fundamental Rating

Taking everything into account, 1RVMD scores 3 out of 10 in our fundamental rating. 1RVMD was compared to 86 industry peers in the Biotechnology industry. The financial health of 1RVMD is average, but there are quite some concerns on its profitability. 1RVMD does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

1RVMD had negative earnings in the past year.
In the past year 1RVMD has reported a negative cash flow from operations.
In the past 5 years 1RVMD always reported negative net income.
In the past 5 years 1RVMD always reported negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -26.65%, 1RVMD is in line with its industry, outperforming 53.49% of the companies in the same industry.
1RVMD's Return On Equity of -37.58% is fine compared to the rest of the industry. 1RVMD outperforms 62.79% of its industry peers.

		Industry Rank	Sector Rank
ROA	-26.65%
ROE	-37.58%
ROIC	N/A

ROA(3y)-25.08%

ROA(5y)-24.01%

ROE(3y)-28.89%

ROE(5y)-28.2%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for 1RVMD so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

1RVMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
1RVMD has more shares outstanding than it did 1 year ago.
1RVMD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for 1RVMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 18.93 indicates that 1RVMD is not in any danger for bankruptcy at the moment.
1RVMD's Altman-Z score of 18.93 is amongst the best of the industry. 1RVMD outperforms 94.19% of its industry peers.
1RVMD has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of 1RVMD (0.16) is better than 62.79% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.16
Debt/FCF	N/A
Altman-Z	18.93

ROIC/WACCN/A

WACC8.88%

2.3 Liquidity

A Current Ratio of 8.05 indicates that 1RVMD has no problem at all paying its short term obligations.
1RVMD has a Current ratio of 8.05. This is amongst the best in the industry. 1RVMD outperforms 89.53% of its industry peers.
A Quick Ratio of 8.05 indicates that 1RVMD has no problem at all paying its short term obligations.
1RVMD has a Quick ratio of 8.05. This is amongst the best in the industry. 1RVMD outperforms 89.53% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	8.05
Quick Ratio	8.05

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

1RVMD shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -44.01%.
Looking at the last year, 1RVMD shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.

EPS 1Y (TTM)-44.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-71.28%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

1RVMD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.31% yearly.
The Revenue is expected to grow by 456.14% on average over the next years. This is a very strong growth

EPS Next Y-59.96%

EPS Next 2Y-35.33%

EPS Next 3Y-18.97%

EPS Next 5Y14.31%

Revenue Next Year1279.08%

Revenue Next 2Y959.89%

Revenue Next 3Y784.17%

Revenue Next 5Y456.14%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

1RVMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 1RVMD. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as 1RVMD's earnings are expected to decrease with -18.97% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-35.33%

EPS Next 3Y-18.97%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for 1RVMD!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

REVOLUTION MEDICINES INC

BIT:1RVMD (1/12/2026, 7:00:00 PM)

100

+34 (+51.52%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-05 2025-11-05/amc

Earnings (Next)02-24 2026-02-24/amc

Inst Owners100.45%

Inst Owner ChangeN/A

Ins Owners1.85%

Ins Owner ChangeN/A

Market Cap19.33B

Revenue(TTM)N/A

Net Income(TTM)-600.09M

Analysts87.41

Price Target76.84 (-23.16%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-12.02%

Min EPS beat(2)-12.79%

Max EPS beat(2)-11.24%

EPS beat(4)0

Avg EPS beat(4)-9.21%

Min EPS beat(4)-12.79%

Max EPS beat(4)-1.54%

EPS beat(8)1

Avg EPS beat(8)-7.65%

EPS beat(12)4

Avg EPS beat(12)-2.45%

EPS beat(16)6

Avg EPS beat(16)-2.06%

Revenue beat(2)0

Avg Revenue beat(2)-100%

Min Revenue beat(2)-100%

Max Revenue beat(2)-100%

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)11.2%

PT rev (3m)N/A

EPS NQ rev (1m)1.5%

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)N/A

Revenue NQ rev (1m)34.87%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	14.06
P/tB	14.71
EV/EBITDA	N/A

EPS(TTM)-4.45

EYN/A

EPS(NY)-5.63

Fwd EYN/A

FCF(TTM)-3.46

FCFYN/A

OCF(TTM)-3.39

OCFYN/A

SpS0

BVpS7.11

TBVpS6.8

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-26.65%
ROE	-37.58%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-25.08%

ROA(5y)-24.01%

ROE(3y)-28.89%

ROE(5y)-28.2%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score1

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.16
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	277.69%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	8.05
Quick Ratio	8.05
Altman-Z	18.93

F-Score1

WACC8.88%

ROIC/WACCN/A

Cap/Depr(3y)158.77%

Cap/Depr(5y)142.66%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-44.01%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-71.28%

EPS Next Y-59.96%

EPS Next 2Y-35.33%

EPS Next 3Y-18.97%

EPS Next 5Y14.31%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year1279.08%

Revenue Next 2Y959.89%

Revenue Next 3Y784.17%

Revenue Next 5Y456.14%

EBIT growth 1Y-41.53%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-68.61%

EBIT Next 3Y-28.97%

EBIT Next 5Y7.47%

FCF growth 1Y-158.95%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-161.07%

OCF growth 3YN/A

OCF growth 5YN/A

REVOLUTION MEDICINES INC / 1RVMD.MI FAQ

What is the ChartMill fundamental rating of REVOLUTION MEDICINES INC (1RVMD.MI) stock?

ChartMill assigns a fundamental rating of 3 / 10 to 1RVMD.MI.

What is the valuation status for 1RVMD stock?

ChartMill assigns a valuation rating of 0 / 10 to REVOLUTION MEDICINES INC (1RVMD.MI). This can be considered as Overvalued.

Can you provide the profitability details for REVOLUTION MEDICINES INC?

REVOLUTION MEDICINES INC (1RVMD.MI) has a profitability rating of 1 / 10.

REVOLUTION MEDICINES INC (1RVMD.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

REVOLUTION MEDICINES INC / 1RVMD.MI FAQ

What is the ChartMill fundamental rating of REVOLUTION MEDICINES INC (1RVMD.MI) stock?

What is the valuation status for 1RVMD stock?

Can you provide the profitability details for REVOLUTION MEDICINES INC?